Status:
COMPLETED
CT Imaging for Guiding PA-TACE for HCC
Lead Sponsor:
Zhujiang Hospital
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18-80 years
Brief Summary
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criteri...
Eligibility Criteria
Inclusion
- CT scans acquired no more than one month before surgery
- Confirmation of HCC diagnosis by pathological examination
- Curative surgical resection
Exclusion
- Prior antitumor treatment
- Macrovascular thrombosis or metastasis
- Perioperative mortality
- Unqualified image artifacts
- Tumor rupture
- MVI status not reported
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
1770 Patients enrolled
Trial Details
Trial ID
NCT06156748
Start Date
October 1 2019
End Date
June 30 2025
Last Update
July 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510280